Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
89%(8 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
7
64%
Ph phase_2
4
36%

Phase Distribution

7

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 2Efficacy & side effects
4(36.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(2)

Detailed Status

Completed9
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
81.8%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (63.6%)
Phase 24 (36.4%)

Trials by Status

completed982%
terminated218%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

NCT02716428
completedphase_2

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

NCT02593162
completedphase_1

Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus

NCT02016625
completedphase_1

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

NCT01965431
terminatedphase_1

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

NCT01957657
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02716428Phase 2

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Completed
NCT02593162Phase 2

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

Completed
NCT02016625Phase 1

Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus

Completed
NCT01965431Phase 1

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

Completed
NCT01957657Phase 1

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

Terminated
NCT01941615Phase 1

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

Terminated
NCT01859962Phase 2

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Completed
NCT01830127Phase 2

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Completed
NCT01785160Phase 1

Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir

Completed
NCT01795937Phase 1

Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin

Completed
NCT01694706Phase 1

Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11